Suppr超能文献

危重病治疗药物治疗文献中的主要出版物:2023 年。

Major Publications in the Critical Care Pharmacotherapy Literature: 2023.

机构信息

Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.

Department of Critical Care, Mayo Clinic Arizona, Phoenix, AZ.

出版信息

Crit Care Explor. 2024 Oct 3;6(10):e1162. doi: 10.1097/CCE.0000000000001162. eCollection 2024 Oct 1.

Abstract

OBJECTIVES

We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023.

DATA SOURCES

PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update.

STUDY SELECTION

Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article.

DATA EXTRACTION

Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature.

DATA SYNTHESIS

The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion.

CONCLUSIONS

This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.

摘要

目的

总结 2023 年描述危重症患者药物治疗护理的最重要和最有影响力的出版物。

数据来源

PubMed/MEDLINE 和临床药学和药理学治疗文献更新。

研究选择

纳入的研究为评估药物治疗干预并报告临床终点的随机对照试验和前瞻性研究,研究对象为成年危重症患者,研究发表时间为 2023 年 1 月 1 日至 2023 年 12 月 31 日。

数据提取

从系统检索和临床药学和药理学治疗文献更新中提取文章。采用预先设定的三轮改良 Delphi 流程,根据以下考虑因素就最有影响力的出版物达成共识:1)对科学知识的总体贡献和 2)对文献的新颖性。

数据综合

系统检索和临床药学和药理学治疗文献更新共返回 1202 篇文章,其中 1164 篇被排除。其余 38 篇文章进行了三轮改良 Delphi 流程。在每一轮中,文章根据对科学知识的总体贡献和对文献的新颖性进行独立评分。总结纳入的文章并讨论其影响。文章主题包括氢化可的松治疗严重社区获得性肺炎、吸入阿米卡星预防呼吸机相关性肺炎、亚甲蓝治疗脓毒性休克、脓毒性低血压时限制与宽松液体管理、andexanet alfa 治疗与因子 Xa 抑制剂相关的大出血以及创伤患者大出血风险时早期使用四因子凝血酶原复合物浓缩物。

结论

本文综述了 2023 年描述危重症患者药物治疗护理进展的最重要和最有影响力的出版物,总结并展望了其潜在影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b5f/11452093/e242ec2c5bef/cc9-6-e1162-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验